TARGETED THERAPY OF NSCLC WITH EGFR ACTIVATING MUTATIONS IMPROVES THE QUALITY OF LIFE OF PATIENTS

Conversion of the incurable disease in the chronic form and improvement of the life quality parameters on the background of appearance of new drugs is of specific importance for patients with NSCLC with activating mutations. “ESMO thinks that treatment of patients with wide-spread and incurable canc...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: T. Y. SEMIGLAZOVA, A. S. ZHABINA, А. V. BELYAEVA, V. A. KLUGE, K. V. USOVA, D. H. LATIPOVA, G. M. TELETAEVA, A. V. NOVIK, A. I. SEMENOVA, S. A. PROTSENKO
Formatua: Artigo
Hizkuntza:Russo
Argitaratua: Remedium Group LLC 2016-12-01
Saila:Медицинский совет
Gaiak:
itk egfr
pfs
quality of life
nsclc mut +
afatinib
Sarrera elektronikoa:https://www.med-sovet.pro/jour/article/view/1406
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak